Leflunomide en es it fr

Leflunomide Brand names, Leflunomide Analogs

Leflunomide Brand Names Mixture

  • No information avaliable

Leflunomide Chemical_Formula


Leflunomide RX_link


Leflunomide fda sheet

Leflunomide FDA

Leflunomide msds (material safety sheet)

Leflunomide MSDS

Leflunomide Synthesis Reference

No information avaliable

Leflunomide Molecular Weight

270.207 g/mol

Leflunomide Melting Point

165-166 oC

Leflunomide H2O Solubility

21 mg/L (poorly soluble)

Leflunomide State


Leflunomide LogP


Leflunomide Dosage Forms


Leflunomide Indication

For the treatment of active rheumatoid arthritis (RA).

Leflunomide Pharmacology

Leflunomide is a pyrimidine synthesis inhibitor indicated in adults for the treatment of active rheumatoid arthritis (RA). RA is an auto-immune disease characterized by high T-cell activity. T cells have two pathways to synthesize pyrimidines: the salvage pathways and the de novo synthesis. At rest, T lymphocytes meet their metabolic requirements by the salvage pathway. Activated lymphocytes need to expand their pyrimidine pool 7- to 8-fold, while the purine pool is expanded only 2- to 3-fold. To meet the need for more pyrimidines, activated T cells use the de novo pathway for pyrimidine synthesis. Therefore, activated T cells, which are dependent on de novo pyrimidine synthesis, will be more affected by leflunomide's inhibition of dihydroorotate dehydrogenase than other cell types that use the salvage pathway of pyrimidine synthesis.

Leflunomide Absorption

Well absorbed, peak plasma concentrations appear 6-12 hours after dosing

Leflunomide side effects and Toxicity

LD50=100-250 mg/kg (acute oral toxicity)

Leflunomide Patient Information

No information avaliable

Leflunomide Organisms Affected

Humans and other mammals